The 1 Thing Missing From Gilead Sciences' 2018 Priority List
At a recent healthcare conference, Gilead Sciences (NASDAQ: GILD) CEO John Milligan laid out his top three priorities for 2018. Here's what he said (this and all other quotes courtesy of S&P Market Intelligence):
[The] B/F/TAF launch is very important for us. Executing on CAR-T is incredibly important for us. And then it's making sure that we get the NASH [nonalcoholic steatohepatitis] drugs moving forward as quickly as possible so that we can be the leader in NASH. Those are my three priorities for the coming year.
Milligan didn't even mention Gilead's hepatitis C franchise, which is on track to provide the company between $8.5 billion and $9 billion in revenue for full-year 2017.
Source: Fool.com
Gilead Sciences Inc Aktie
71,02 €
0,07 %
Eine klare Neigung zu Buy-Einschätzungen bei Gilead Sciences Inc, ohne Sell-Einschätzungen.
Ein Kursziel von 85 € für Gilead Sciences Inc zeigt ein leicht positives Potenzial im Vergleich zum aktuellen Kurs von 71.02 €.
